Migraine pathophysiology
Migraine is not simply a bad headache — it is a complex neurological event:
- Cortical spreading depression (CSD): A wave of neuronal depolarisation followed by prolonged suppression spreads across the cortex at 3–5 mm/min. CSD generates the migraine aura and triggers downstream trigeminal activation.
- Trigeminal activation:CSD activates trigeminal nociceptors around cerebral blood vessels, releasing CGRP (calcitonin gene-related peptide) — a potent vasodilator. CGRP-mediated dural vasodilation and mast cell activation produce the throbbing pain.
- Neuroinflammation:NF-κB activation in trigeminal nucleus neurons and dural mast cells produces IL-1β, TNF-α, and COX-2-derived prostaglandins that sensitise pain pathways and prolong the attack.
- Mitochondrial dysfunction:Migraine brains show reduced mitochondrial energy capacity between attacks and during prodrome. Oxidative stress in neurons lowers the CSD threshold.
Magnesium and migraine: the strongest connection
Magnesium has the strongest evidence among supplements for migraine prevention:
- 50–60% of migraine patients have reduced ionised magnesium in brain tissue during attacks (measured by MRS spectroscopy) compared to controls
- Magnesium inhibits CSD threshold — low magnesium lowers the threshold for spreading depolarisation
- Magnesium inhibits NMDA receptors (voltage-dependent Mg²⁺ block) — NMDA overactivation is implicated in CSD initiation
- Multiple RCTs show magnesium oxide/citrate at 400–600 mg/day reduces migraine frequency by 30–45% — now in evidence-based migraine prevention guidelines
Spirulina provides approximately 50–65 mg magnesium per 10 g — about 12–16% of the 400 mg/day therapeutic dose. For migrants with chronic migraine, this is a meaningful contribution alongside dietary magnesium but not a replacement for therapeutic-dose magnesium supplementation.
Phycocyanin: NF-κB neuroinflammation
The neuroinflammatory component of migraine involves NF-κB activation in trigeminal neurons and dural tissue. Phycocyanobilin inhibits NADPH oxidase (reducing superoxide-driven NF-κB activation) and directly inhibits IKK in neural tissue. This is the same mechanism documented in animal models of neurological inflammation (Parkinson’s, Alzheimer’s, MS). No migraine-specific trial exists, but the NF-κB inhibition pathway is mechanistically relevant.
Riboflavin (B2) and mitochondrial energy
Riboflavin (B2) at 400 mg/day is a Grade A evidence-based migraine prevention treatment — it improves mitochondrial energy efficiency, raising the CSD threshold. Spirulina provides approximately 0.3–0.5 mg riboflavin per 10 g — a negligible fraction of the therapeutic dose. For migraine management, riboflavin supplementation (400 mg/day) is a separate and important intervention that spirulina does not provide.
GLA and prostaglandin balance
Prostaglandins — particularly PGE2 from COX-2 — sensitise dural nociceptors during migraine and are involved in the initiation of the attack. GLA→DGLA→PGE1 pathway provides the anti-inflammatory prostaglandin that competes with PGE2 production. This is the same mechanism relevant in PMS — where prostaglandin excess drives pain. Spirulina’s GLA contributes to prostaglandin balance at the mechanistic level.
Practical protocol for migraine
Spirulina as part of a comprehensive nutritional migraine prevention strategy:
- Add dedicated magnesium supplementation: Magnesium glycinate or citrate 400 mg/day is the evidence-based intervention. Spirulina alone provides insufficient magnesium for therapeutic effect.
- Consider riboflavin B2 400 mg/day: The second evidence-based nutritional supplement in migraine guidelines — spirulina does not replace this.
- Spirulina 5–8 g/day:For background magnesium contribution, GLA prostaglandin balance, and phycocyanin neuroinflammation reduction alongside the primary interventions.
- CoQ10 consideration:100–300 mg/day CoQ10 also supports mitochondrial energy and has grade B evidence in migraine. Spirulina does not contain CoQ10.
Migraine medications: no significant interactions
- Triptans (sumatriptan, rizatriptan):No documented interaction. Spirulina’s mechanisms are preventive; triptans are acute abortive. Safe to use concurrently.
- Topiramate or valproate (preventive):No documented interaction. These are neurostabilisers — spirulina’s anti-inflammatory effects are complementary in mechanism.
- Beta-blockers (propranolol):Spirulina’s potassium content (~150 mg/10g) is not clinically significant relative to beta-blocker cardiac effects. No interaction.
- CGRP antagonists (erenumab, fremanezumab):Modern biologics for frequent migraine — no interaction concern. Spirulina does not significantly affect CGRP levels.
The honest summary
Spirulina has mechanistically relevant contributions to migraine prevention — magnesium (sub-therapeutic dose contribution), GLA prostaglandin modulation, and phycocyanin neuroinflammation reduction. It should not be the primary nutritional intervention for established migraine: dedicated magnesium, riboflavin, and CoQ10 have stronger evidence at specific doses. Spirulina complements these as a background nutritional support — not a replacement for proven interventions.